Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

Although programmed cell death protein 1 (PD−1)/PD-ligand 1 (PD-L1) blockade is effective in a subset of patients with hepatocellular carcinoma (HCC), its therapeutic response is still unsatisfactory. Alternatively, the potential impact of the lenvatinib in patients who showed tumor progression on P...

Full description

Bibliographic Details
Main Authors: Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki, Naoshi Nishida
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
hepatocellular carcinoma
lenvatinib
PD-1/PD-L1 blockade
molecular targeted agents
vascular endothelial growth factor
Online Access:https://www.mdpi.com/2072-6694/12/10/3048

Internet

https://www.mdpi.com/2072-6694/12/10/3048

Similar Items